NEUROLOGICAL INVOLVEMENT IN EVANS SYNDROME AND CHRONIC HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION, EVOLUTION AND GENETICS

EHA Library, Thomas Pincez, 182003

ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTICOAGULANT?

EHA Library, Joe Sharif, 182054

CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN)

EHA Library, Alfonso Vignoli, 182053

GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS.

EHA Library, Angel F Remacha, 182052

INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS WARRANTED?

EHA Library, Anmol Baranwal, 182050

DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK

EHA Library, Buddhika Badugama, 182048

ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION

EHA Library, Alfonso Vignoli, 182047

GWAS RESULTS IN RED BLOOD CELL PHENOTYPES AND THEIR RELATIONSHIP WITH THROMBOSIS

EHA Library, Angel F Remacha, 182046

C57BL/6 SUBTRAINS SHOW DIFFERENCES IN HEMATOPOIETIC REPOPULATION

EHA Library, Antonio Morales Hernandez, 182045

MESENCHYMAL STEM CELLS (MSCS) ATTENUATE CUTANEOUS SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE (SCL-GVHD) THROUGH INHIBITION OF IMMUNE CELL INFILTRATION IN A MOUSE MODEL

EHA Library, Ji-Young Lim, 182044

EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED THROUGH EPIGENETIC MODIFCATIONS.

EHA Library, Isabel Alvarez Laderas, 182043

IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC STEM CELL GENE THERAPY MEDIATED BY MSCS

EHA Library, Maria Fernandez-Garcia, 182042

GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE MARROW TRANSPLANTATION IS NOT INFLUENCED BY TH9 CELLS

EHA Library, Gudrun Strauss, 182041

DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS

EHA Library, Beatriz Sanchez-Vega, 181966

FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY

EHA Library, Andrzej J. Jakubowiak, 181967

PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTSTHE ANTI-MYELOMA EFFICACY OF DARATUMUMAB

EHA Library, Estefania Garcia-Guerrero, 181968

BCL2 EXPRESSION IS A POTENTIAL PREDICTIVE BIOMARKER OF RESPONSE TO VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Jeremy Ross, 181969

THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY

EHA Library, Berdien Oortgiesen, 181970

TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS

EHA Library, Paolo Milani, 181971

MYOCARDIAL UPTAKE OF 99MTC-DPD IN PATIENTS WITH AL AMYLOIDOSIS

EHA Library, Carlos de Miguel Jiménez, 181972

WHEN PERFORMANCE OF CYTOGENETICS MATTERS: A POPULATION-BASED STUDY IN THE NETHERLANDS ON NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Mirian Brink, 181973

AN UPDATED ADJUSTED COMPARISON SUGGESTS DARATUMUMAB IS ASSOCIATED WITH PROLONGED SURVIVAL COMPARED WITH STANDARD OF CARE THERAPIES IN HEAVILY PRE-TREATED AND HIGH REFRACTORY MULTIPLE MYELOMA PATIENTS

EHA Library, Shaji K. Kumar, 181974

PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS

EHA Library, Paula Rodríguez-Otero, 181975

MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS

EHA Library, Takaaki Maekawa, 181976

ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID- MICE

EHA Library, Taghi Manshouri, 181977

ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS

EHA Library, Hiraku Takei, 181978

QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS

EHA Library, Nuria Socoro Yuste, 181979

THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS

EHA Library, Mathias Schneeweiss-Gleixner, 181980

DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA

EHA Library, Alicia Senín, 181981

RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS

EHA Library, Joaquin Martinez-Lopez, 181982

INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING

EHA Library, Conchi Fernández Rodríguez, 181983

METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE

EHA Library, Suzanne McPherson, 181984

ELUCIDATING THE AGE INDUCED HEMATOPOIETIC CELL-INTRINSIC AND EXTRINSIC MECHANISMS IN MYELOPROLIFERATIVE NEOPLASM INITIATION AND PROGRESSION

EHA Library, Tata Nageswara Rao, 181985

PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL

EHA Library, Moshe Talpaz, 181986

COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS:RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)

EHA Library, Frank Stegelmann, 181987

PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), IN PATIENTS WITH MYELOFIBROSIS (MF) AND BASELINE (BL) THROMBOCYTOPENIA: FOCUS ON RUXOLITINIB (RUX)-TREATED PATIENTS IN THE PHASE 3 PERSIST-2 TRIAL

EHA Library, Claire Harrison, 181988

SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (≥ 75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY

EHA Library, Pia Raanani, 181989

PROGNOSTIC RISK MODELS FOR TRANSPLANT DECISION-MAKING IN MYELOFIBROSIS

EHA Library, Juan Carlos Hernandez-Boluda, 181990

LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY

EHA Library, Gunnar Birgegard, 181991

EPIDEMIOLOGY, OUTCOME AND RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS

EHA Library, Nicola Polverelli, 181992

TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS—FINDINGS FROM THE INTERNATIONAL MPN LANDMARK SURVEY

EHA Library, Steffen Koschmieder, 181993

SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B - AN UPDATE FROM THE PEGINVERA STUDY

EHA Library, Heinz Gisslinger, 181994

NO IMPROVEMENT IN SURVIVAL OVER TIME FOR PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS WHO TRANSFORM TO ACCELERATED OR BLAST PHASE

EHA Library, Caroline Mcnamara, 181995

MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY

EHA Library, Olivier Hermine, 181996

THERAPY RESPONSE AND LONG-TERM OUTCOME OF 71 ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE INSTITUTION EXPERIENCE

EHA Library, Maciej Machaczka, 181997

WHOLE-EXOME SEQUENCING IN CHILDREN WITH IMMUNE CYTOPENIA: THE APPLICABILITY AND CLINICAL IMPACT

EHA Library, Michael Svaton, 181998

SEQUENCING OF THE HYPOXIA PATHWAY GENES IN PATIENTS WITH CONGENITAL ERYTHROCYTOSES BY NEXT GENERATION SEQUENCING

EHA Library, Francois Girodon, 181999

CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE.

EHA Library, Alberto Orfao, 182000

MONOALLELIC VARIANTS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REPORT FROM THE ITALIAN REGISTRY

EHA Library, Laura vinas, 182001

PRIMARY AND CONGENITAL ERYTHROCYTOSIS IN PEDIATRICS: THE EXPERIENCE OF ITALIAN CENTERS

EHA Library, Giulia Geranio, 182002

RESULTS OF USING BRIDGING THERAPY WITH SODIUM BEMIPARIN AT THERAPEUTIC-DOSE

EHA Library, Maria Almudana Garcia Ruiz, 182055

AUTOIMMUNE NEUTROPENIA OF CHILDHOOD SECONDARY TO OTHER AUTOIMMUNE DISORDERS: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY

EHA Library, Piero Farruggia, 182004

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT DURING PREGNANCY

EHA Library, Maria Vinogradova, 182005

LONG-TERM RESPONSE TO ORAL ELIGLUSTAT IN TREATMENT-NAÏVE ADULTS WITH GAUCHER DISEASE TYPE 1: FINAL EFFICACY AND SAFETY RESULTS FROM A PHASE 2 CLINICAL TRIAL AFTER 8 YEARS OF TREATMENT

EHA Library, Elena Lukina, 182006

REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA: REVIEU (REVOLADE™ [ELTROMBOPAG] IN SELECTED COUNTRIES IN THE EUROPEAN UNION) STUDY

EHA Library, EMILIO OJEDA GUTIERREZ, 182007

BIOLOGICAL CHARACTERIZATION OF ITP PATIENTS THAT ARE NON-RESPONDERS TO TRADITIONAL THERAPIES

EHA Library, Nuria Revilla, 182008

SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS

EHA Library, Silvia Cantoni, 182009

THROMBOEMBOLIC EVENT MANAGEMENT AND OUTCOMES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ELTROMBOPAG (EPAG): RESULTS FROM THE EXTEND STUDY

EHA Library, Mansoor N Saleh, 182010

ATORVASTATIN IMPROVE THE PROGNOSIS OF ADULT PATIENTS WITH CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA VIA ENHANCING BONE MARROW ENDOTHELIAL CELL FUNCTION

EHA Library, Xie Cao, 182012

PLATELET DESIALYLATION IS A NOVEL MECHANISM AND A THERAPEUTIC TARGET IN THROMBOCYTOPENIA DURING SEPSIS: AN OPEN-LABEL, MULTICENTER, RANDOMIZED CONTROLLED TRIAL

EHA Library, Xin Li, 182013

SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, James Bussel, 182014

IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING PATHWAY INHIBITOR TREATMENT

EHA Library, William Wierda, 182015

THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING PRACTICE

EHA Library, Alessandra Lurlo and Cristina Buccelli, 182016

BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES

EHA Library, Fanni Rencz, 182017

AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION - IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS.

EHA Library, Dunnya DE-SILVA, 182018

COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Matthew Seftel, 182019

THE THERAPEUTIC UTILITY OF A SYSTEMATIC PROTOCOL FOR GERIATRIC ASSESMENT IN ONCOHEMATOLOGIC PATIENTS

EHA Library, Claudia Milagros Terán Benzaquen, 182020

RADIATION EXPOSURE FROM CT IMAGING AND CHILDHOOD LEUKEMIA: A NATIONWIDE CASE-CONTROL STUDY

EHA Library, Atte Nikkilä, 182021

HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, PARAMESWARAN HARI, 182022

MANAGEMENT, ECONOMIC AND SOCIAL IMPACT OF SUB-CUTANEOUS RITUXIMAB ADMINISTRATION IN LYMPHOPROLIFERATIVE MALIGNANCIES

EHA Library, Ombretta Annibali, 182023

EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND IMWG´14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA

EHA Library, Belen Ballina, 182024

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN

EHA Library, Maria Gabelli, 182025

PREDICTIVE FACTORS FOR DEVELOPING VENO-OCCLUSIVE DISEASE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Partow Kebriaei, 182026

DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA FROM AN EXPANDED-ACCESS PROGRAM

EHA Library, PAUL RICHARDSON, 182027

ALLO-HCT FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - 12 YEARS OF EXPERIENCE

EHA Library, Miroslaw Markiewicz, 182028

A COMPARISON OF CLINICAL OUTCOMES BETWEEN MATCHED SIBLING DONOR (MSD) AND UNRELATED DONOR (URD) STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA

EHA Library, Seung-Hwan Shin, 182029

HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE THALASSEMIA PATIENTS

EHA Library, Suradej hongeng, 182030

AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES WITH NO ADDED TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

EHA Library, Vipul Sheth, 182031

PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

EHA Library, Christina CHO, 182032

THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR URSODEOXYCHOLIC ACID?

EHA Library, Rocio Parody Porras, 182033

FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION. COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND BENEFICT OF HAPLOIDENTICAL DONOR.

EHA Library, MD Caballero, 182034

EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL SUBGROUP RESULTS

EHA Library, PAUL RICHARDSON, 182035

GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR CELL LINES FROM TRANSGENIC MICE

EHA Library, Eszter Doma, 182036

INHIBITING BCL2 AND NK CELLS IMPROVES STEM CELL TRANSPLANT OUTCOMES.

EHA Library, Joanne Davis, 182037

MESENCHYMAL STROMAL CELL IRRADIATION INTERFERES WITH THE ADIPOGENIC/OSTEOGENIC DIFFERENTIATION BALANCE IMPROVING THEIR HEMATOPOIETIC-SUPPORTING ABILITY

EHA Library, Silvia Preciado Pérez, 182038

DYSFUNCTION OF BONE MARROW MESENCHYMAL STEM CELLS FROM PATIENTS WITH PROLONGED ISOLATED THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN BE IMPROVED BY N-ACETYL-L-CYSTEINE

EHA Library, Yang Song, 182039

INHIBITORS OF APOPTOSIS PROTEINS (IAPS) MODULATE GASTROINTESTINAL GVHD IN MURINE EXPERIMENTAL BMT MODELS

EHA Library, Tomomi Toubai, 182040

THE SIMM STUDY: SURVEY OF INTEGRATIVE MEDICINE IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Krisstina gowin, 181792

DISCOVERY OF ORALLY BIOAVAILABLE SMALL MOLECULES FOR INHIBITION OF COMPLEMENT C5

EHA Library, Alonso Ricardo, 181787

IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ΑLPHA-BETA T-CELL DEPLETED HAPLO-HSCT

EHA Library, Pietro Merli, 181782

STUDY OF THE EFFECT OF MIRNAS TARGETING RPS14 ON CELLULAR BIOLOGICALBEHAVIOR OF MYELODYSPLASTIC SYNDROMES

EHA Library, Yanbo Nie, 181777

ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY

EHA Library, Simona SOVERINI, 181772

STANDARD-RISK RANDOMIZATION OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN TRIAL AIEOP-BFM ALL 2000 INDICATES EQUAL OUTCOME WITH REDUCED-INTENSITY DELAYED INTENSIFICATION IN ETV6-RUNX1-POSITIVE PATIENTS

EHA Library, Kirsten Bleckmann, 181767

QUIZARTINIB AND BRIDGE TO TRANSPLANT IN FLT3-ITD AML PATIENTS AFTER FAILURE OF SALVAGE CHEMOTHERAPY: A HISTORICAL COMPARISON WITH UK NATIONAL CANCER RESEARCH INSTITUTE (NCRI) DATA

EHA Library, Robert Hills, 181762

L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY

EHA Library, Maddocks Kami J., 181757

SAFETY RESULTS OF TERMINATED PHASE 2 STUDY OF IDELALISIB PLUS RITUXIMAB IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH DEL(17P)

EHA Library, Peter Hillmen, 181752

A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Philippe Moreau, 181747

SINGLE AGENT ORAL SELINEXOR EXHIBITS DURABLE RESPONSES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF BOTH GCB AND NON-GCB SUBTYPES: THE PHASE 2B SADAL STUDY

EHA Library, Marie Maerevoet, 181756

BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)

EHA Library, Paula Cramer, 181751

EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR

EHA Library, Katja Weisel, 181746